Literature DB >> 17592917

The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study.

Astrid B Birkenaes1, Stein Opjordsmoen, Cathrine Brunborg, John A Engh, Halldora Jonsdottir, P Andreas Ringen, Carmen Simonsen, Anja Vaskinn, Kåre I Birkeland, Svein Friis, Kjetil Sundet, Ole A Andreassen.   

Abstract

OBJECTIVE: In schizophrenia, increased rates of somatic mortality have been shown to correspond with a high prevalence of cardiovascular risk factors, including smoking and the metabolic syndrome. In bipolar disorder, the amount of cardiovascular risk is still largely unknown. This study compares the prevalence of smoking and metabolic disturbances in bipolar disorder and schizophrenia in a representative sample of patients under naturalistic conditions. It also compares the prevalence of risk factors in each diagnostic group with the general population.
METHOD: Longitudinal data on clinical groups from October 2002 through December 2005 were from the Oslo TOP Study (DSM-IV bipolar disorder [N = 110] and schizophrenia [N = 163]). Reference data were from the 2000 to 2001 Oslo Health Study (18,770 individuals of the same area). Background variables, prevalence of smoking, and age-adjusted levels of metabolic risk factors were compared between diagnostic groups. Risk factors in both groups were then compared with the general population.
RESULTS: Patients with bipolar disorder had higher levels of education, better social functioning, fewer psychiatric symptoms, and less use of medication than patients with schizophrenia. There was no significant difference between diagnostic groups in the prevalence of smoking, obesity, metabolic syndrome, or diabetes. The mean level of high density lipoprotein cholesterol was lower in schizophrenia (p < .001), and systolic blood pressure was higher in bipolar disorder (p < .05). Both diagnostic groups had a prevalence of cardiovascular risk factors about twice that of the general population.
CONCLUSION: The prevalence of cardiovascular risk factors was alarmingly high for bipolar disorder and schizophrenia patients compared with the general population, and the prevalence was approximately the same in both diagnostic groups.

Entities:  

Mesh:

Year:  2007        PMID: 17592917     DOI: 10.4088/jcp.v68n0614

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  45 in total

Review 1.  Medication Adherence in Patients with Bipolar Disorder: A Comprehensive Review.

Authors:  Jennifer B Levin; Anna Krivenko; Molly Howland; Rebecca Schlachet; Martha Sajatovic
Journal:  CNS Drugs       Date:  2016-09       Impact factor: 5.749

2.  Identifying common genetic variants in blood pressure due to polygenic pleiotropy with associated phenotypes.

Authors:  Ole A Andreassen; Linda K McEvoy; Wesley K Thompson; Yunpeng Wang; Sjur Reppe; Andrew J Schork; Verena Zuber; Elizabeth Barrett-Connor; Kaare Gautvik; Pål Aukrust; Tom H Karlsen; Srdjan Djurovic; Rahul S Desikan; Anders M Dale
Journal:  Hypertension       Date:  2014-01-06       Impact factor: 10.190

3.  Increased cardiometabolic dysfunction in first-degree relatives of patients with psychotic disorders.

Authors:  Suraj Sarvode Mothi; Neeraj Tandon; Jaya Padmanabhan; Ian T Mathew; Brett Clementz; Carol Tamminga; Godfrey Pearlson; John Sweeney; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2015-04-19       Impact factor: 4.939

4.  Manic/hypomanic symptom burden and cardiovascular mortality in bipolar disorder.

Authors:  Jess G Fiedorowicz; David A Solomon; Jean Endicott; Andrew C Leon; Chunshan Li; John P Rice; William H Coryell
Journal:  Psychosom Med       Date:  2009-06-26       Impact factor: 4.312

Review 5.  Cardiovascular morbidity and mortality in bipolar disorder.

Authors:  Miriam Weiner; Lois Warren; Jess G Fiedorowicz
Journal:  Ann Clin Psychiatry       Date:  2011-02       Impact factor: 1.567

6.  The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample.

Authors:  Jess G Fiedorowicz; Jianping He; Kathleen R Merikangas
Journal:  J Psychosom Res       Date:  2010-09-18       Impact factor: 3.006

7.  Expanding Cessation Pharmacotherapy Via Videoconference Educational Outreach to Prescribers.

Authors:  Mary F Brunette; Nino Dzebisashvili; Haiyi Xie; Sarah Akerman; Joelle C Ferron; Stephen Bartels
Journal:  Nicotine Tob Res       Date:  2015-08       Impact factor: 4.244

Review 8.  Suicide in stroke survivors: epidemiology and prevention.

Authors:  Maurizio Pompili; Paola Venturini; Dorian A Lamis; Gloria Giordano; Gianluca Serafini; Martino Belvederi Murri; Mario Amore; Paolo Girardi
Journal:  Drugs Aging       Date:  2015-01       Impact factor: 3.923

9.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

10.  Coronavirus immunoreactivity in individuals with a recent onset of psychotic symptoms.

Authors:  Emily G Severance; Faith B Dickerson; Raphael P Viscidi; Ioannis Bossis; Cassie R Stallings; Andrea E Origoni; Anne Sullens; Robert H Yolken
Journal:  Schizophr Bull       Date:  2009-06-02       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.